NASDAQ:ARGS - Argos Therapeutics Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$0.1360 +0.01 (+5.02 %)
(As of 08/14/2018 04:23 AM ET)
Previous Close$0.1295
Today's Range$0.1101 - $0.1360
52-Week Range$0.10 - $5.80
Volume10,315 shs
Average Volume496,858 shs
Market Capitalization$2.29 million
P/E RatioN/A
Dividend YieldN/A
Beta1.53
Argos Therapeutics logoArgos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma; and in Phase II clinical trial to treat early stage renal cell carcinoma and muscle invasive bladder cancer. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina.

Receive ARGS News and Ratings via Email

Sign-up to receive the latest news and ratings for ARGS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARGS
CUSIPN/A
Phone919-287-6300

Debt

Debt-to-Equity Ratio-1.31
Current Ratio1.80
Quick Ratio1.80

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.90 million
Price / Sales0.76
Cash FlowN/A
Price / CashN/A
Book Value($1.63) per share
Price / Book-0.08

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-40,570,000.00
Net Margins-2,135.68%
Return on EquityN/A
Return on Assets-171.85%

Miscellaneous

Employees39
Outstanding Shares10,590,000
Market Cap$2.29 million

Argos Therapeutics (NASDAQ:ARGS) Frequently Asked Questions

What is Argos Therapeutics' stock symbol?

Argos Therapeutics trades on the NASDAQ under the ticker symbol "ARGS."

When did Argos Therapeutics' stock split? How did Argos Therapeutics' stock split work?

Shares of Argos Therapeutics reverse split on the morning of Friday, January 19th 2018. The 1-20 reverse split was announced on Thursday, January 18th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of Argos Therapeutics stock prior to the reverse split would have 5 shares after the split.

How were Argos Therapeutics' earnings last quarter?

Argos Therapeutics Inc. (NASDAQ:ARGS) released its quarterly earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($4.20) earnings per share for the quarter, topping analysts' consensus estimates of ($4.50) by $0.30. The biopharmaceutical company had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.10 million. View Argos Therapeutics' Earnings History.

When is Argos Therapeutics' next earnings date?

Argos Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 15th 2018. View Earnings Estimates for Argos Therapeutics.

Who are some of Argos Therapeutics' key competitors?

Who are Argos Therapeutics' key executives?

Argos Therapeutics' management team includes the folowing people:
  • Mr. Jeffrey D. Abbey, Pres, CEO & Director (Age 56)
  • Dr. Charles A. Nicolette Ph.D., Chief Scientific Officer and VP of R&D (Age 56)
  • Dr. Richard D. Katz, VP & CFO (Age 54)
  • Ms. Lori R. Harrelson CPA, VP of Fin. & Principal Accounting Officer (Age 49)
  • Mr. John D. Menditto, VP of Corp. Communications and Investor Relations

Has Argos Therapeutics been receiving favorable news coverage?

Press coverage about ARGS stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Argos Therapeutics earned a news and rumor sentiment score of 0.10 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 47.07 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for Argos Therapeutics.

How do I buy shares of Argos Therapeutics?

Shares of ARGS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Argos Therapeutics' stock price today?

One share of ARGS stock can currently be purchased for approximately $0.1360.

How big of a company is Argos Therapeutics?

Argos Therapeutics has a market capitalization of $2.29 million and generates $1.90 million in revenue each year. Argos Therapeutics employs 39 workers across the globe.

How can I contact Argos Therapeutics?

Argos Therapeutics' mailing address is 4233 TECHNOLOGY DR, DURHAM NC, 27704. The biopharmaceutical company can be reached via phone at 919-287-6300.


MarketBeat Community Rating for Argos Therapeutics (NASDAQ ARGS)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  255 (Vote Outperform)
Underperform Votes:  158 (Vote Underperform)
Total Votes:  413
MarketBeat's community ratings are surveys of what our community members think about Argos Therapeutics and other stocks. Vote "Outperform" if you believe ARGS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARGS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/14/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.